The ECHA classification proposal raises significant questions for the development of the hemp sector that deserve detailed analysis.
📷 AECANI Visual Lab
Proposal Context
ANSES (France) has presented a classification proposal that raises relevant considerations about the free movement of goods in Europe. The methodology used, based on high-dose studies, merits technical analysis.
What does ANSES propose?
The French agency proposes to classify CBD as:
- Reprotoxic 1B (may damage fertility or the fetus)
- May cause damage to organs after prolonged exposure
⚠️ Methodological Considerations
The proposal is based primarily on studies with extremely high doses of CBD, equivalent to ingesting hundreds of bottles a day, far in excess of any normal human use. These doses present inconsistencies with actual consumption patterns.
Aspects to Consider of the Proposal
1. Unrealistic Doses
The studies use doses of CBD hundreds of times higher than any normal consumer would ingest under normal wellness or cosmetic conditions.
The extrapolation of massive dose data to normal uses is a practice that the scientific community criticizes for its lack of rigor.
📷 AECANI Visual Lab
2. Considerations on Extrapolation
Results from studies in rodents with high doses are extrapolated to possible effects in humans, without considering the documented history of use of the substance.
3. Divergence with WHO Evaluations
The WHO concluded in 2018 that CBD has a good safety profile and does not exhibit abuse potential or harmful effects at normal doses.
"There are divergences between the ANSES proposal and the conclusions of international bodies such as the WHO, as well as with the doctrine established by the CJEU.
Potential Implications
If the classification proceeds, it would have effects on the market:
Cosmetics
CBD would be included among the CMR substances of the EU Cosmetics Regulation, which would affect its use in this sector.
Industry
European companies in the sector would need to adapt their business lines to the new regulatory conditions.
📚 References
- ECHA - Harmonized classification process (CLH)
- ANSES (France) - Proposed classification of CBD
- OMS (2018) - Critical Review of Cannabidiol (CBD)